Rapt Therapeutics Inc.
- Address
- 561 Eccles Avenue
Sponsor Overview
Specializations
Asthma
The sponsor’s clinical research is centered on asthma, with a focus on adults living with T2-high asthma and persistent symptoms despite maintenance treatment. The funded study addresses partially controlled asthma and the need to improve control in patients receiving standard inhaled therapy.
- Moderate-to-severe asthma
- T2-high airway inflammation
- Loss of asthma control
Research activity in this area reflects interest in respiratory disease management, especially clinical outcomes related to symptom control and exacerbation risk in patients using inhaled corticosteroids and long-acting beta2 agonists.
Inflammatory airway disease
The sponsor is engaged in therapeutic development for type 2 inflammatory disease mechanisms that contribute to chronic airway disease. Its clinical focus includes patients whose asthma remains inadequately controlled because of ongoing airway inflammation.
- Type 2 inflammation
- Airway hyperresponsiveness
- Persistent respiratory symptoms
This area highlights interest in biologically defined subgroups of asthma and in therapeutic strategies aimed at improving control in patients with inflammatory airway disease.
Adult respiratory medicine
Clinical research activity is directed toward adults with chronic respiratory conditions, particularly those requiring ongoing controller therapy. The sponsor’s trial portfolio indicates attention to disease burden in the adult asthma population.
- Adult asthma care
- Maintenance inhaled therapy
- Partially controlled disease
The therapeutic emphasis is on patients who remain symptomatic despite established treatment regimens, with outcomes tied to day-to-day disease control and stability.
Clinical development in pulmonary medicine
The sponsor’s research landscape includes pulmonary medicine and the evaluation of therapies intended to improve control of chronic inflammatory lung disease. The active trial network spans multiple countries and collaborating sites, supporting work in a globally relevant respiratory indication.
- Chronic lung disease
- Respiratory symptom control
- Inhaled controller therapy
Current activity is concentrated on clinical questions relevant to asthma management, including the need for better control in patients already receiving standard-of-care inhaled treatment.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy |  Bulgaria Czechia Poland | Not Recruiting |
Data & Insights
This sponsor works with 4 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 23 sites across their trial portfolio.
Therapeutic Focus
- 1.Respiratory Tract Diseases1 trial277 other sponsors
Partnered Research Centres
23 centres- Address
- Ul. Tomasza Drobnika 49, 60-693 Poznan
- Address
- Ul. Lesna 8, 59-300 Lubin
- Address
- Ul. Piasta 9a, 15-044 Bialystok
- Address
- Triaditsa, Ulitsa Sveti Georgi Sofiyski 1, 1431 Sofia
- Address
- Ulitsa Sinanishko Ezero 11a, 1680 Sofia
- Address
- al. J. Słowackiego 39, 31-159 Krakow
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Rapt Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.